Analyst Price Target is $8.50
▲ +30.37% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Alpha Teknova in the last 3 months. The average price target is $8.50, with a high forecast of $12.00 and a low forecast of $5.00. The average price target represents a 30.37% upside from the last price of $6.52.
Current Consensus is
Buy
The current consensus among 2 contributing investment analysts is to buy stock in Alpha Teknova. This rating has held steady since March 2025, when it changed from a Moderate Buy consensus rating.
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Read More
